%0 Journal Article
%T Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023
%A Otto-Knapp, Ralf
%A Edwards, Suzanne
%A Kuchukhidze, Giorgi
%A Kröger, Stefan
%A Häcker, Brit
%A Bivoli, Stela
%A Yedilbayev, Askar
%D 2024
%G eng
%X The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.
%K Europe
%K MDR/RR-TB
%K access
%K drug availability
%K pretomanid
%K tuberculosis
%K 610 Medizin und Gesundheit
%I Robert Koch-Institut
%J Eurosurveillance - Europe's journal on infectious disease surveillance, epidemiology, prevention and control
%P 1--5
%R 10.2807/1560-7917.ES.2024.29.17.2400211